HT-6184 Placebo

DRUG2 trials

Sponsors

Halia Therapeutics, Inc.

Conditions

Normal Healthy SubjectsPain

Phase 1

Study to Evaluate HT-6184 in Healthy Subjects

CompletedNCT05447546

Halia Therapeutics, Inc.Normal Healthy Subjects

Start: 2022-06-15End: 2023-07-20Updated: 2023-08-28

Phase 2

Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction

CompletedNCT06241742

Halia Therapeutics, Inc.Pain

Start: 2024-02-12End: 2024-04-30Updated: 2025-03-30

Related Papers

Ofirnoflast, a novel inflammasome inhibitor, rewires transcriptional programs and shows clinical and preclinical efficacy in myeloid neoplasms

Blood2025-11-03